Paper36979508
Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing.
Puglisi A and 7 others. Biomolecules, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing. Papers, record 36979508. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979508
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyclodextrins | Major topic |
| Nanoparticles | Major topic |
| Cricetinae | |
| Animals | |
| Cricetulus | |
| Precision Medicine | |
| Blood-Brain Barrier | |
| Cholesterol |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 202834/Z/16/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27999408 | Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. | Molecules | 2016 | https://conductscience.org/library/papers/27999408 | PubMed |
| 2 | 22578502 | Relevance of exocytotic glutamate release from retinal glia. | Neuron | 2012 | https://conductscience.org/library/papers/22578502 | PubMed |
| 3 | 15573101 | Cyclodextrin-based pharmaceutics: past, present and future. | Nat Rev Drug Discov | 2004 | https://conductscience.org/library/papers/15573101 | PubMed |
| 4 | 32324281 | Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study. | J Inherit Metab Dis | 2020 | https://conductscience.org/library/papers/32324281 | PubMed |
| 5 | 21629911 | Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. | Nanoscale | 2011 | https://conductscience.org/library/papers/21629911 | PubMed |
| 6 | 28803710 | Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. | Lancet | 2017 | https://conductscience.org/library/papers/28803710 | PubMed |
| 7 | 22484464 | Theranostic applications of nanoparticles in cancer. | Drug Discov Today | 2012 | https://conductscience.org/library/papers/22484464 | PubMed |
| 8 | 19750228 | Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. | PLoS One | 2009 | https://conductscience.org/library/papers/19750228 | PubMed |
| 9 | 26166537 | Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. | Chem Rev | 2015 | https://conductscience.org/library/papers/26166537 | PubMed |
| 10 | 19835370 | Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. | Nano Lett | 2009 | https://conductscience.org/library/papers/19835370 | PubMed |
| 11 | 9211849 | Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. | Science | 1997 | https://conductscience.org/library/papers/9211849 | PubMed |
| 12 | 34769082 | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769082 | PubMed |
| 13 | 20861879 | Revitalizing membrane rafts: new tools and insights. | Nat Rev Mol Cell Biol | 2010 | https://conductscience.org/library/papers/20861879 | PubMed |
| 14 | 30216584 | Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C. | Macromol Rapid Commun | 2019 | https://conductscience.org/library/papers/30216584 | PubMed |
| 15 | 31131260 | A Novel Three-Dimensional Glioma Blood-Brain Barrier Model for High-Throughput Testing of Tumoricidal Capability. | Front Oncol | 2019 | https://conductscience.org/library/papers/31131260 | PubMed |
| 16 | 34869239 | Cyclodextrin-Appended Superparamagnetic Iron Oxide Nanoparticles as Cholesterol-Mopping Agents. | Front Chem | 2021 | https://conductscience.org/library/papers/34869239 | PubMed |
| 17 | 26027824 | Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease. | Biol Pharm Bull | 2015 | https://conductscience.org/library/papers/26027824 | PubMed |
| 18 | 1537866 | Isolation and characterization of Chinese hamster ovary cells defective in the intracellular metabolism of low density lipoprotein-derived cholesterol. | J Biol Chem | 1992 | https://conductscience.org/library/papers/1537866 | PubMed |
| 19 | 27834398 | Cancer nanomedicine: progress, challenges and opportunities. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/27834398 | PubMed |
| 20 | 27799764 | Optimizing superparamagnetic iron oxide nanoparticles as drug carriers using an in vitro blood-brain barrier model. | Int J Nanomedicine | 2016 | https://conductscience.org/library/papers/27799764 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41900791 | Cyclodextrins as Modulators of Regulated Cell Death: Implications for Immunometabolism and Therapeutic Innovation. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41900791 | PubMed |
| 40521219 | Breaking barriers: exploring blood-brain barrier crossing mechanisms with nanomedicine for effective glioma treatment. | 3 Biotech | 2025 | https://conductscience.org/library/papers/40521219 | PubMed |
| 39707045 | Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation. | Discov Nano | 2024 | https://conductscience.org/library/papers/39707045 | PubMed |
| 38455415 | Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/38455415 | PubMed |
| 37509092 | Cyclodextrins as Drug Release Modulators and Toxic Compound Removal Agents. | Biomolecules | 2023 | https://conductscience.org/library/papers/37509092 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36979508
GET https://conductscience.org/api/papers/v1/36979508/references?page=2